STC.UNM, the University of New Mexico's technology-transfer office, will be hosting its fall seminar series in September, October and November.  The seminars are free and open to the UNM community and the public but registration is required.  Box lunches will be served at all seminars.

Sept. 22, 12 - 1 p.m.
Domenici Education Center West, Room 3010, UNM HSC Campus

"New Mexico Financing Environment for Biomedical Start-ups"
Richard D. Gill, President & CEO, TruTouch Technologies, Inc.


Richard Gill


Gill will start with an overview of the characteristics necessary for successful drug development and commercialization, discuss financial issues new biomedical companies need to pay attention to, and present different investment strategies for start-ups to consider. He will wrap up his presentation with a summary of TruTouch Technologies' financial turnaround.

As President & CEO of TruTouch Technologies, Inc., Gill brings three decades of strategic management, research, and technology commercialization experience in the life sciences industry. Gill previously served as President & CEO of ProNAi Therapeutics, where he raised $11.5 million and achieved IND approval of their lead drug in less than two years. Prior to ProNAI Gill led Signet Laboratories to acquisition by Covance.

Gill has also served as the President of AnVil, ActiveCyte, and Genome Therapeutics Corporation, raising 10's of millions of dollars for the development of their novel medical technologies and orchestrating attractive investor exits.

His earlier career highlights include serving as general manager and senior vice president of BTG International, where he led the global biosciences sector. In that role Gill helped lead the management buyout of British Technology Group plc from the British government, the firm's expansion into international markets, and its subsequent initial public offering. Gill began his career at Unilever.  Gill holds a Ph.D. in Endocrinology and a B.Sc. with honors in Physiology and Biochemistry from Reading University, UK.

Oct. 19, 12 - 1 p.m.
Student Union Building (SUB), Room Acoma A & B, UNM Main Campus

"The Opportunity Assessment"
Paul Short, venture partner, The Verge Fund

Do you have a technology that you think has commercialization potential? Short will discuss the importance of assessing the market for newly developed technologies before a business plan is even written. Based on concepts developed by Steven Gary Blank and Ralph Grabowski, Short's presentation will focus on how to talk to potential customers and what kinds of questions to ask, providing examples from his own experiences as illustration.

Short was the first Entrepreneur-in-Residence for the Verge Fund, having joined in late 2005. He is now a Venture Partner responsible for the Fund's El Paso and southern New Mexico strategy.

Prior to joining the Verge Fund, Short founded InnovASIC, originally a services company that provided integrated circuit designs to customer specifications. With only a $5,000 investment, he bootstrapped this company from zero to $1,000,000 in sales. However he saw that the market was evolving in a way that provided better opportunities. Modifying the classic fabless semiconductor business model, he created a new model, creating clones of microprocessors that large companies had discontinued. He raised $3.5M in venture capital, and transformed the company.

During a period where the semiconductor industry contracted 45 percent, InnovASIC grew product revenue from zero to $5 million. To this day, the company's best selling products are the ones Short specified, and InnovASIC has sold more than a million 186 processors and has up to 90 percent gross margins. In 2005, recognizing the need for an additional skill set to carry the company forward to the next level of growth, Short raised a new $4M round of funding, recruited a replacement for himself as CEO, and stepped into a temporary business development role.

Upon joining the Verge Fund, Short began reviewing deals and developing new business concepts, primarily in the electronics and semiconductor space. In 2006, he developed the concept for Quadric Semiconductor and formed that company with Verge seed funding. Based upon market input, and the current state of the financing market for fabless semiconductor companies, Short changed the direction of the business and re-launched it as Metaphor Computing. He developed a unique technology, and Metaphor today owns multiple patents based on that effort.

In an example of the Verge model, in March of 2010 Verge was informed that a portfolio company, Altela, was in some trouble. Rather than having the company shut down, Short put Metaphor in hibernation and assumed a one-year role as Chief Operating Officer for the company. During that period, he developed, built, and installed the next generation product upon which the company's future rests. The product was responsible for growing revenue from zero in 2009 to over two million in 2010. Short also dramatically improved Altela's manufacturing system, helped drive the sales process, fostered a more productive culture, and helped raise $11M from a new set of investors.

Short holds BS and MS Electrical Engineering degrees from New Mexico State University, and held positions as an engineer with NMSU's Physical Science Laboratory and with Honeywell in Albuquerque.

Nov. 3, 12 - 1 p.m.
Student Union Building (SUB), Room Acoma A & B, UNM Main Campus

"The Changing World of Venture Capital and Angel Investing"
John Chavez, president, New Mexico Angels


John Chavez


Chavez will discuss the changing roles of angel investing and venture capital investing in early stage technology companies due to changes in the economy.  Angel investors are focusing their investment goals increasingly on helping these start-ups bring their technologies to the prototype stage and into the next phase of funding from venture and corporate investors to bring the product to the marketplace.

Chavez has been the President of the New Mexico Angels since 2008, but has been an active Angel investor since 2003. Since becoming President, the Angels have seen an increase of over 100% in investment deals in new companies. The Angels are now leading investment deals, rather than following venture capitals into them. Showcase forums allow Angel technology partners, Los Alamos National Lab, Sandia National Laboratories, and the University of New Mexico, the opportunity to present technologies available for licensing to Angel members and guests. Chavez, with the aid of an advisement team, screens potential investments for presentation at the quarterly dinner meetings. The Angels also host educational seminars to teach both investors and entrepreneurs alike about Angel funding.

Outside of the Angels, Chavez is Managing Partner and Founder of Phase One Ventures, based in Santa Fe, NM. Phase One is a start-up fund aimed at bio and nanotechnologies. Additionally, he is the President of Tafoya and Brainerd Partners LLC, a nationwide business development consulting firm.  Prior to his adventures in entrepreneurship, Chavez served as the Cabinet Secretary of the Taxation and Revenue Department of the state of New Mexico by Governor Gary Johnson.

Chavez is a member of the Board of Directors of the University of New Mexico Anderson School Foundation, as well as the All Faiths Receiving Home Foundation. He was recently asked to speak at the International Economic Development Council's 2011 Summit.   Chavez holds a BA in Economics, a BBA in Finance and an MBA from New Mexico State University.

Nov. 14, 12 - 1 p.m.
Domenici Education Center Northeast, Room 2410, UNM HSC Campus

"A Brief Update on Dealing with the U. S. Patent Office:  Issues and Perspectives"
Henry D. Coleman, partner, Coleman, Sudol, Sapone P. C.


Henry Coleman


Coleman will present a brief update on the latest developments at the U. S. Patent Office. The rest of the session will be devoted to Q & A, allowing attendees to ask Coleman questions with follow-up discussion.  He is a Partner with the IP law firm Coleman, Sudol, Sapone P.C. and has been in patent practice since 1985, with an emphasis on high-technology chemistry, pharmaceuticals, biotechnology, polymers, cosmetics, and medical devices and instrumentation.

Coleman has more than 24 years of experience in patent procurement and related proceedings, including interferences, before the United States Patent and Trademark Office in a variety of chemical, pharmaceutical, biotechnological and cosmetic technologies. He has extensive negotiating and licensing experience in technology transfer and joint venture research relationships, having negotiated agreements in the areas of cosmetics, pharmaceuticals, biotechnology, medical devices, contact lenses, polymer coatings, paint strippers, printing technology and related products. Coleman has patent and contract litigation experience (including arbitration experience) in the technical areas of contact lens copolymers, specialty chemicals, cosmetics and pharmaceuticals. Coleman also has extensive experience in conducting due diligence and providing opinions on patent matters, including licensing. Coleman has been counsel in interference proceedings in the U.S. Patent and Trademark Office in the biotechnology and pharmaceutical arts.

Coleman was a summer associate (1984) with the Boston patent law firm Fish & Richardson where he handled patent prosecution and technology assessment in the biotechnology area (monoclonal antibodies, expression vectors, genetic engineering techniques, DNA probe technology) and was an associate attorney with Kenyon & Kenyon from 1985 to 1987 where he handled patent prosecution, licensing, and opinion-related matters in a number of technical areas including polymer chemistry, polymeric resins, pharmaceuticals, biotechnology, metallurgical products, materials science, cosmetics, medical devices and instrumentation and food technology. Coleman was also a partner in the firm McAulay Fisher Nissen Goldberg & Kiel, LLP from 1996-1997 where he practiced intellectual property law primarily in the chemical and pharmaceutical areas.

Coleman has served as a patent expert witness (Hamman & Benn, Chicago, Ill., 1995-1997) in a pharmaceutical patent infringement litigation as well as an expert witness (Habush, Habush & Davis, Madison, Wisconsin l984-85) in a medical malpractice case.   He is admitted to practice before the United States Patent and Trademark Office, the United States District Courts for the District of New Jersey, the Southern District of New York and the Eastern District of New York and before the Appellate Courts of the States of New York and New Jersey.

Coleman has completed graduate research in synthetic organic chemistry (nucleoside, carbohydrate, and heterocyclic), bio-organic chemistry (RNA and DNA phosphodiester and phosphotriester chemistry), biochemistry/pharmacology (RNA and DNA biochemistry, modified polymeric nucleoside cell uptake studies, cell culture techniques, and RNA and DNA purification), and drug design (design of anti-neoplastic DNA and RNA probes modified with unnatural nucleoside analogs for inhibition of reverse transcriptase and neoplasia). His Ph.D. thesis, "Studies on the Chemical Synthesis of Oligoribonucleotides Containing 5-Mercaptopyrimidine Bases," dealt with research on the design and chemical synthesis of modified deoxyribonucleic acid and ribonucleic acid.

Coleman has experience in polymer research directing the development of novel gas permeable contact lens polymers, and served as Director of Polymer Research and Development at Permeable Technologies, Inc., directing polymer development in the contact lens area in concert with a joint venture research group from E.I. DuPont de Nemours & Company. He is a former executive vice-president of Permeable Technologies, and a co-inventor of three United States patents in the polymer chemistry area.

Coleman graduated from the State University of New York at Buffalo in 1977 with a B.S. in Pharmaceutical/Medicinal Chemistry, magna cum laude, and a B.A. in Political Science, magna cum laude, and in 1982 with a Ph.D. in Pharmaceutical/Medicinal Chemistry. He attended the University of Wisconsin School of Law, graduating in 1985, cum laude.   Coleman is admitted to practice in New York, Wisconsin, and to the Patent Bar. He is also a member of the New Jersey Patent Law Association, New York Patent, Trademark and Copyright Association, Association of University Technology Managers and the American Chemical Society.

To register online for any of these seminars, visit STC Events and Seminars or e-mail Denise Bissell or call (505) 272-7310.